<400> 227
Phe Glu Trp Thr Pro Gly Tyr Trp Gln Xaa Tyr
1 5 10

<210> 228
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:IL-1 ANTAGONIST PEPTIDE

<220>
<223> At position 1, optionally acetylated at N-terminus

<220>
<223> At position 10, Xaa=azetidine

<400> 228
Phe Glu Trp Thr Pro Gly Tyr Trp Gln Xaa Tyr
1 5 10

<210> 229
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:IL-1 ANTAGONIST PEPTIDE

<220>
<223> At position 6, products="MeGly"

<220>
<223> At position 10, Xaa=azetidine

<400> 229
Phe Glu Trp Thr Pro Xaa Trp Tyr Gln Xaa Tyr
1 5 10

<210> 230
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:IL-1 ANTAGONIST PEPTIDE

<220>
<223> At position 6, Xaa=MeGly

<220>
<223> At position 10, Xaa=azetidine

<400> 230
Phe Glu Trp Thr Pro Xaa Trp Tyr Gln Xaa Tyr
1 5 10

<210> 231
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:IL-1 ANTAGONIST PEPTIDE

<400> 231
Phe Glu Trp Thr Pro Gly Tyr Tyr Gln Pro Tyr
1 5 10

<210> 232
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:IL-1 ANTAGONIST PEPTIDE

<400> 232
Phe Glu Trp Thr Pro Gly Trp Trp Gln Pro Tyr

1 5 10

<210> 233
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:IL-1 ANTAGONIST PEPTIDE

<400> 233
Phe Glu Trp Thr Pro Asn Tyr Trp Gln Pro Tyr
1 5 10

<210> 234
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:IL-1 ANTAGONIST PEPTIDE

<220>
<223> At position 5, Xaa=pipecolic acid

<220>
<223> At position 10, Xaa=azetidine

<400> 234
Phe Glu Trp Thr Xaa Val Tyr Trp Gln Xaa Tyr
1 5 10

<210> 235
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:IL-1 ANTAGONIST PEPTIDE

<220>
<223> At position 5, Xaa=pipecolic acid

<220>
<223> At position 10, Xaa=azetidine

<400> 235
Phe Glu Trp Thr Xaa Gly Tyr Trp Gln Xaa Tyr
1 5 10

<210> 236
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:IL-1 ANTAGONIST PEPTIDE

<220>
<223> At position 6, Xaa=Aib

<220>
<223> At position 10, Xaa=azetidine

<400> 236
Phe Glu Trp Thr Pro Xaa Tyr Trp Gln Xaa Tyr
1 5 10

<210> 237
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:IL-1 ANTAGONIST PEPTIDE

<220>
<223> At position 5, Xaa=MeGly

<220>
<223> At position 10, Xaa=azetidine

<400> 237
Phe Glu Trp Thr Xaa Gly Tyr Trp Gln Xaa Tyr
1 5 10

<210> 238
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:IL-1 ANTAGONIST PEPTIDE

<220>
<223> At position 11, amino group added at C-terminus

<400> 238
Phe Glu Trp Thr Pro Gly Tyr Trp Gln Pro Tyr
1 5 10

<210> 239
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:IL-1 ANTAGONIST PEPTIDE

<220>
<223> At position 11, amino group added at C-terminus

<400> 239
Phe Glu Trp Thr Pro Gly Tyr Trp Gln His Tyr
1 5 10

<210> 240
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:IL-1 ANTAGONIST PEPTIDE

<220>
<223> At position 10, Xaa is an azetidine residue

<220>
<223> At position 11 amino group added at C-terminus

<400> 240
Phe Glu Trp Thr Pro Gly Trp Tyr Gln Xaa Tyr
1 5 10

<210> 241
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:IL-1 ANTAGONIST PEPTIDE

<220>
<223> At position 1, optionally acetylated at N-terminus

<220>
<223> At position 10, Xaa is an azetidine residue

<220>
<223> At position 11 amino group added at C-terminus

<400> 241
Phe Glu Trp Thr Pro Gly Trp Tyr Gln Xaa Tyr
1 5 10

<210> 242
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:IL-1 ANTAGONIST

PEPTIDE

<220>
<223> At position 8, Xaa is a phyosphotyrosyl residue

<220>
<223> At position 10, Xaa is an azetidine residue

<220>
<223> At position 11, amino group added at C-terminus

<400> 242
Phe Glu Trp Thr Pro Gly Trp Xaa Gln Xaa Tyr
1 5 10

<210> 243
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:IL-1 ANTAGONIST PEPTIDE

<220>
<223> At position 10, Xaa is an azetidine residue

<220>
<223> At position 11 amino group added at C-terminus

<400> 243
Phe Ala Trp Thr Pro Gly Tyr Trp Gln Xaa Tyr
1 5 10

<210> 244
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:IL-1 ANTAGONIST PEPTIDE

<220>

<223> At position 10, Xaa is an azetidine residue

<220>
<223> At position 11 amino group added at C-terminus

<400> 244
Phe Glu Trp Ala Pro Gly Tyr Trp Gln Xaa Tyr
1 5 10

<210> 245
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:IL-1 ANTAGONIST PEPTIDE

<220>
<223> At position 10, Xaa is an azetidine residue

<220>
<223> At position 11 amino group added at C-terminus

<400> 245
Phe Glu Trp Val Pro Gly Tyr Trp Gln Xaa Tyr
1 5 10

<210> 246
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:IL-1 ANTAGONIST PEPTIDE

<220>
<223> At position 10, Xaa is an azetidine residue

<220>
<223> At position 11 amino group added at C-terminus

<400> 246

Phe Glu Trp Thr Pro Gly Tyr Trp Gln Xaa Tyr
1 5 10

<210> 247
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:IL-1 ANTAGONIST PEPTIDE

<220>
<223> At position 1 acetylated at N-terminus

<220>
<223> At position 10, Xaa is an azetidine residue

<220>
<223> At position 11 amino group added at C-terminus

<400> 247
Xaa Glu Trp Thr Pro Gly Tyr Trp Gln Xaa Tyr
1 5 10

<210> 248
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:IL-1 ANTAGONIST PEPTIDE

<220>
<223> At position 6, D amino acid residue

<220>
<223> At position 10, Xaa is an azetidine residue

<220>
<223> At position 11 amino group added at C-terminus

<400> 248

Phe Glu Trp Thr Pro Ala Trp Tyr Gln Xaa Tyr
1 5 10

<210> 249
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:IL-1 ANTAGONIST PEPTIDE

<220>
<223> At position 6, Xaa is a sarcosine residue

<220>
<223> At position 10, Xaa is an azetidine residue

<220>
<223> At position 11 amino group added at C-terminus

<400> 249
Phe Glu Trp Thr Pro Xaa Trp Tyr Gln Xaa Tyr
1 5 10

<210> 250
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:IL-1 ANTAGONIST PEPTIDE

<220>
<223> At position 11 amino group added at C-terminus

<400> 250
Phe Glu Trp Thr Pro Gly Tyr Tyr Gln Pro Tyr
1 5 10

<210> 251

<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:IL-1 ANTAGONIST PEPTIDE

<220>
<223> At position 11 amino group added at C-terminus

<400> 251
Phe Glu Trp Thr Pro Gly Trp Trp Gln Pro Tyr
1 5 10

<210> 252
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:IL-1 ANTAGONIST PEPTIDE

<220>
<223> At position 11 amino group added at C-terminus

<400> 252
Phe Glu Trp Thr Pro Asn Tyr Trp Gln Pro Tyr
1 5 10

<210> 253
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:IL-1 ANTAGONIST PEPTIDE

<220>
<223> At position 6, D amino acid residue

<220>

<223> At position 10, Xaa is an azetidine residue

<220>
<223> At position 11, amino group added at C-terminus

<400> 253
Phe Glu Trp Thr Pro Val Tyr Trp Gln Xaa Tyr
1 5 10

<210> 254
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:IL-1 ANTAGONIST PEPTIDE

<220>
<223> At position 5, Xaa is a pipecolic acid residue

<220>
<223> At position 10, Xaa is an azetidine residue

<220>
<223> At position 11, amino group added at C-terminus

<400> 254
Phe Glu Trp Thr Xaa Gly Tyr Trp Gln Xaa Tyr
1 5 10

<210> 255
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:IL-1 ANTAGONIST PEPTIDE

<220>
<223> At position 6, Xaa=pipecolic acid

<220>

<223> At position 10, Xaa=azetidine

<400> 255
Phe Glu Trp Thr Pro Xaa Tyr Trp Gln Xaa Tyr
1 5 10

<210> 256
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:IL-1 ANTAGONIST PEPTIDE

<220>
<223> At position 5, Xaa=MeGly

<220>
<223> At position 10, Xaa=azetidine

<400> 256
Phe Glu Trp Thr Xaa Gly Tyr Trp Gln Xaa Tyr
1 5 10

<210> 257
<211> 15
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:INTEGRIN BINDING PEPTIDE

<400> 257
Phe Glu Trp Thr Pro Gly Tyr Trp Gln Pro Tyr Ala Leu Pro Leu
1 5 10 15

<210> 258
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:IL-1 ANTAGONIST PEPTIDE

<220>
<223> At position 1, Xaa is a 1-naphthylalanine residue

<220>
<223> At position 10, Xaa is an azetidine residue

<220>
<223> At position 11, amino group added at C-terminus

<400> 258
Xaa Glu Trp Thr Pro Gly Tyr Tyr Gln Xaa Tyr
1 5 10

<210> 259
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:IL-1 ANTAGONIST PEPTIDE

<220>
<223> At position 10, Xaa is a azetidine residue

<220>
<223> At position 11, amino group added at C-terminus

<400> 259
Tyr Glu Trp Thr Pro Gly Tyr Tyr Gln Xaa Tyr
1 5 10

<210> 260
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:IL-1 ANTAGONIST

PEPTIDE

<220>
<223> At position 10, Xaa is an azetidine residue

<220>
<223> At position 11, amino group added at C-terminus

<400> 260
Phe Glu Trp Val Pro Gly Tyr Tyr Gln Xaa Tyr
1 5 10

<210> 261
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:IL-1 ANTAGONIST PEPTIDE

<220>
<223> At position 6, D amino acid residue

<220>
<223> At position 10, Xaa is an azetidine residue

<220>
<223> At position 11, amino group added at C-terminus

<400> 261
Phe Glu Trp Thr Pro Ser Tyr Tyr Gln Xaa Tyr
1 5 10

<210> 262
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:IL-1 ANTAGONIST PEPTIDE

<220>

<223> At position 6, D amino acid residue

<220>
<223> At position 10, Xaa is an azetidine residue

<220>
<223> At position 11, amino group added at C-terminus

<400> 262
Phe Glu Trp Thr Pro Asn Tyr Tyr Gln Xaa Tyr
1 5 10

<210> 263
<211> 4
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:IL-1 ANTAGONIST PEPTIDE

<400> 263
Thr Lys Pro Arg
1

<210> 264
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:IL-1 ANTAGONIST PEPTIDE

<400> 264
Arg Lys Ser Ser Lys
1 5

<210> 265
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 265
Arg Lys Gln Asp Lys
1 5

<210> 266
<211> 6
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 266
Asn Arg Lys Gln Asp Lys
1 5

<210> 267
<211> 6
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 267
Arg Lys Gln Asp Lys Arg
1 5

<210> 268
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:IL-1 ANTAGONIST

PEPTIDE

<400> 268
Glu Asn Arg Lys Gln Asp Lys Arg Phe
1 5

<210> 269
<211> 6
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 269
Val Thr Lys Phe Tyr Phe
1 5

<210> 270
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 270
Val Thr Lys Phe Tyr
1 5

<210> 271
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 271

Val Thr Asp Phe Tyr
1 5

<210> 272
<211> 17
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:IL-1 ANTAGONIST PEPTIDE

<400> 272
Ser Gly Ser Gly Val Leu Lys Arg Pro Leu Pro Ile Leu Pro Val Thr
1 5 10 15

Arg

<210> 273
<211> 17
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:MCA/MCP PROTEASE INHIBITOR PEPTIDE

<400> 273
Arg Trp Leu Ser Ser Arg Pro Leu Pro Pro Leu Pro Leu Pro Pro Arg
1 5 10 15

Thr

<210> 274
<211> 20
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:MCA/MCPPROTEASE

INHIBITOR PEPTIDE

<400> 274
Gly Ser Gly Ser Tyr Asp Thr Leu Ala Leu Pro Ser Leu Pro Leu His
1 5 10 15

Pro Met Ser Ser
20

<210> 275
<211> 20
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:MCA/MCP
PROTEASE INHIBITOR PEPTIDE

<400> 275
Gly Ser Gly Ser Tyr Asp Thr Arg Ala Leu Pro Ser Leu Pro Leu His
1 5 10 15

Pro Met Ser Ser
20

<210> 276
<211> 20
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:MCA/MCP
PROTEASE INHIBITOR PEPTIDE

<400> 276
Gly Ser Gly Ser Ser Gly Val Thr Met Tyr Pro Lys Leu Pro Pro His
1 5 10 15

Trp Ser Met Ala
20

<210> 277

<211> 20
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:MCA/MCP
PROTEASE INHIBITOR PEPTIDE

<400> 277
Gly Ser Gly Ser Ser Gly Val Arg Met Tyr Pro Lys Leu Pro Pro His
1 5 10 15

Trp Ser Met Ala
20

<210> 278
<211> 20
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:MCA/MCP
PROTEASE INHIBITOR PEPTIDE

<400> 278
Gly Ser Gly Ser Ser Ser Met Arg Met Val Pro Thr Ile Pro Gly Ser
1 5 10 15

Ala Lys His Gly
20

<210> 279
<211> 6
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:ANTI-HBV
PEPTIDE

<400> 279
Leu Leu Gly Arg Met Lys
1 5

<210> 280
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:ANTI-HBV
PEPTIDE

<400> 280
Ala Leu Leu Gly Arg Met Lys Gly
1 5

<210> 281
<211> 6
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:ANTI-HBV
PEPTIDE

<400> 281
Leu Asp Pro Ala Phe Arg
1 5

<210> 282
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:SH3 ANTAGONIST

<400> 282
Arg Pro Leu Pro Pro Leu Pro
1 5

<210> 283
<211> 7

<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:SH3 ANTAGONIST

<400> 283
Arg Glu Leu Pro Pro Leu Pro
1 5

<210> 284
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:MSH3 ANTAGONIST

<400> 284
Ser Pro Leu Pro Pro Leu Pro
1 5

<210> 285
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:SH3 ANTAGONIST

<400> 285
Gly Pro Leu Pro Pro Leu Pro
1 5

<210> 286
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:SH3 ANTAGONIST

<400> 286
Arg Pro Leu Pro Ile Pro Pro
1 5

<210> 287
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:MAST CELL ANTAGONISTS/MAST CELL PROTEASE INHIBITOR

<400> 287
Arg Pro Leu Pro Ile Pro Pro
1 5

<210> 288
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:SH3 ANTAGONIST

<400> 288
Arg Arg Leu Pro Pro Thr Pro
1 5

<210> 289
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:SH3 ANTAGONIST

<400> 289
Arg Gln Leu Pro Pro Thr Pro
1 5

<210> 290
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:SH3 ANTAGONIST

<400> 290
Arg Pro Leu Pro Ser Arg Pro
1 5

<210> 291
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:SH3 ANTAGONIST

<400> 291
Arg Pro Leu Pro Thr Arg Pro
1 5

<210> 292
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:SH3 ANTAGONIST

<400> 292
Ser Arg Leu Pro Pro Leu Pro
1 5

<210> 293
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:SH3 ANTAGONIST

<400> 293
Arg Ala Leu Pro Ser Pro Pro
1 5

<210> 294
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:SH3 ANTAGONIST

<400> 294
Arg Arg Leu Pro Arg Thr Pro
1 5

<210> 295
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:SH3 ANTAGONIST

<400> 295
Arg Pro Val Pro Pro Ile Thr
1 5

<210> 296
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:SH3 ANTAGONIST

<400> 296
Ile Leu Ala Pro Pro Val Pro
1 5

<210> 297
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:SH3 ANTAGONIST

<400> 297
Arg Pro Leu Pro Met Leu Pro
1 5

<210> 298
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:SH3 ANTAGONIST

<400> 298
Arg Pro Leu Pro Ile Leu Pro
1 5

<210> 299
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:SH3 ANTAGONIST

<400> 299
Arg Pro Leu Pro Ser Leu Pro
1 5

<210> 300
<211> 7
<212> PRT

<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:SH3 ANTAGONIST

<400> 300
Arg Pro Leu Pro Ser Leu Pro
1 5

<210> 301
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:SH3 ANTAGONIST

<400> 301
Arg Pro Leu Pro Met Ile Pro
1 5

<210> 302
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:SH3 ANTAGONIST

<400> 302
Arg Pro Leu Pro Leu Ile Pro
1 5

<210> 303
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:SH3 ANTAGONIST

<400> 303

Arg Pro Leu Pro Pro Thr Pro
1 5

<210> 304
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:SH3 ANTAGONIST

<400> 304
Arg Ser Leu Pro Pro Leu Pro
1 5

<210> 305
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:SH3 ANTAGONIST

<400> 305
Arg Pro Gln Pro Pro Pro Pro
1 5

<210> 306
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:SH3 ANTAGONIST

<400> 306
Arg Gln Leu Pro Ile Pro Pro
1 5

<210> 307

<211> 12
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:SH3 ANTAGONIST

<400> 307
Xaa Xaa Xaa Arg Pro Leu Pro Pro Leu Pro Xaa Pro
1 5 10

<210> 308
<211> 12
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:SH3 ANTAGONIST

<400> 308
Xaa Xaa Xaa Arg Pro Leu Pro Pro Ile Pro Xaa Xaa
1 5 10

<210> 309
<211> 12
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:SH3 ANTAGONIST

<400> 309
Xaa Xaa Xaa Arg Pro Leu Pro Pro Leu Pro Xaa Xaa
1 5 10

<210> 310
<211> 12
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:SH3 ANTAGONIST

<400> 310
Arg Xaa Xaa Arg Pro Leu Pro Pro Leu Pro Xaa Pro
1 5 10

<210> 311
<211> 12
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:SH3 ANTAGONIST

<400> 311
Arg Xaa Xaa Arg Pro Leu Pro Pro Leu Pro Pro Pro
1 5 10

<210> 312
<211> 12
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:SH3 ANTAGONIST

<400> 312
Pro Pro Pro Tyr Pro Pro Pro Pro Ile Pro Xaa Xaa
1 5 10

<210> 313
<211> 12
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:SH3 ANTAGONIST

<400> 313
Pro Pro Pro Tyr Pro Pro Pro Pro Val Pro Xaa Xaa
1 5 10

<210> 314
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:SH3 ANTAGONIST

<400> 314
Leu Xaa Xaa Arg Pro Leu Pro Xaa Xaa Pro
1 5 10

<210> 315
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:SH3 ANTAGONIST

<220>
<223> At position 1, Xaa is an aliphatic amino acid residue

<400> 315
Xaa Xaa Xaa Arg Pro Leu Pro Xaa Leu Pro
1 5 10

<210> 316
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:SH3 ANTAGONIST

<220>
<223> At position 4, Xaa is an aromatic amino acid residue

<220>
<223> At position 9, Xaa is an aliphatic amino acid residue

<400> 316
Pro Pro Xaa Xaa Tyr Pro Pro Pro Xaa Pro
1 5 10

<210> 317
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:SH3 ANTAGONIST

<220>
<223> At position 1, Xaa is a basic amino acid residue

<220>
<223> At position 4, Xaa is an aliphatic amino acid residue

<400> 317
Xaa Pro Pro Xaa Pro Xaa Lys Pro Xaa Trp Leu
1 5 10

<210> 318
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:SH3 ANTAGONIST

<220>
<223> At position 4, Xaa is an aliphatic amino acid residue

<220>
<223> At position 6, Xaa is an aliphatic amino acid residue

<220>
<223> At position 8, Xaa is a basic amino acid residue

<400> 318

Arg Pro Xaa Xaa Pro Xaa Arg Xaa Ser Xaa Pro
1 5 10

<210> 319
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:SH3 ANTAGONIST

<400> 319
Pro Pro Val Pro Pro Arg Pro Xaa Xaa Thr Leu
1 5 10

<210> 320
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:SH3 ANTAGONIST

<220>
<223> At positions 1, 3 and 6, Xaa is an aliphatic amino acid residue

<400> 320
Xaa Pro Xaa Leu Pro Xaa Lys
1 5

<210> 321
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:SH3 ANTAGONIST

<220>
<223> At position 1, Xaa is a basic amino acid residue

<220>
<223> At position 2, Xaa is an aromatic amino acid residue

<400> 321
Xaa Xaa Asp Xaa Pro Leu Pro Xaa Leu Pro
1 5 10

<210> 322
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:INHIBITOR OF PLATELET AGGREGATION

<400> 322
Cys Xaa Xaa Arg Gly Asp Cys
1 5

<210> 323
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:SRC ANTAGONIST

<400> 323
Arg Pro Leu Pro Pro Leu Pro
1 5

<210> 324
<211> 6
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:SRC ANTAGONIST

<400> 324

Pro Pro Val Pro Pro Arg
1 5

<210> 325
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:ANTI-CANCER PEPTIDE

<400> 325
Xaa Phe Xaa Asp Xaa Trp Xaa Xaa Leu Xaa Xaa
1 5 10

<210> 326
<211> 20
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:p16-MIMETIC PEPTIDE

<400> 326
Lys Ala Cys Arg Arg Leu Phe Gly Pro Val Asp Ser Glu Gln Leu Ser
1 5 10 15

Arg Asp Cys Asp
20

<210> 327
<211> 20
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:p16-MIMETIC PEPTIDE

<400> 327

Arg Glu Arg Trp Asn Phe Asp Phe Val Thr Glu Thr Pro Leu Glu Gly
1 5 10 15

Asp Phe Ala Trp
20

<210> 328
<211> 20
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:p16-MIMETIC PEPTIDE

<400> 328
Lys Arg Arg Gln Thr Ser Met Thr Asp Phe Tyr His Ser Lys Arg Arg
1 5 10 15

Leu Ile Phe Ser
20

<210> 329
<211> 20
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:SH3 ANTAGONIST

<400> 329
Thr Ser Met Thr Asp Phe Tyr His Ser Lys Arg Arg Leu Ile Phe Ser
1 5 10 15

Lys Arg Lys Pro
20

<210> 330
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:p16-MIMETIC PEPTIDE

<400> 330
Arg Arg Leu Ile Phe
1 5

<210> 331
<211> 36
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:p16-MIMETIC PEPTIDE

<400> 331
Lys Arg Arg Gln Thr Ser Ala Thr Asp Phe Tyr His Ser Lys Arg Arg
1 5 10 15

Leu Ile Phe Ser Arg Gln Ile Lys Ile Trp Phe Gln Asn Arg Arg Met
20 25 30

Lys Trp Lys Lys
35

<210> 332
<211> 24
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:p16-MIMETIC PEPTIDE

<400> 332
Lys Arg Arg Leu Ile Phe Ser Lys Arg Gln Ile Lys Ile Trp Phe Gln
1 5 10 15

Asn Arg Arg Met Lys Trp Lys Lys
20

<210> 333
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:POLYGLYCINE LINKER

<400> 333
Gly Gly Gly Lys Gly Gly Gly Gly
1 5

<210> 334
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:POLYGLYCINE LINKER

<400> 334
Gly Gly Gly Asn Gly Ser Gly Gly
1 5

<210> 335
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:POLYGLYCINE LINKER

<400> 335
Gly Gly Gly Cys Gly Gly Gly Gly
1 5

<210> 336
<211> 5

<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:FC PCR PRIMER

<400> 336
Gly Pro Asn Gly Gly
1 5

<210> 337
<211> 42
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:TPO-MIMETIC

<400> 337
Phe Gly Gly Gly Gly Gly Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu
1 5 10 15

Ala Ala Arg Ala Gly Gly Gly Gly Gly Gly Gly Ile Glu Gly Pro
20 25 30

Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala
35 40

<210> 338
<211> 42
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:TPO-MIMETIC

<400> 338
Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala Gly Gly
1 5 10 15

Gly Gly Gly Gly Gly Gly Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu
20 25 30

Ala Ala Arg Ala Gly Gly Gly Gly Gly Phe

140

35 40

<210> 339
<211> 50
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:TPO-MIMETIC

<400> 339
Phe Gly Gly Gly Gly Gly Gly Gly Thr Tyr Ser Cys His Phe Gly Pro
1 5 10 15

Leu Thr Trp Val Cys Lys Pro Gln Gly Gly Gly Gly Gly Gly Gly Gly
20 25 30

Thr Tyr Ser Cys His Phe Gly Pro Leu Thr Trp Val Cys Lys Pro Gln
35 40 45

Gly Gly
50

<210> 340
<211> 50
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:EPO-MIMETIC

<400> 340
Gly Gly Thr Tyr Ser Cys His Phe Gly Leu Thr Trp Val Cys Lys
1 5 10 15

Pro Gln Gly Gly Gly Gly Gly Gly Gly Gly Thr Tyr Ser Cys His Phe
20 25 30

Gly Pro Leu Thr Trp Val Cys Lys Pro Gln Gly Gly Gly Gly Gly Gly
35 40 45

Gly Phe
50

<210> 341
<211> 28
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:TPO-MIMETIC PEPTIDES

<400> 341
Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala Ile Glu
1 5 10 15

Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala
20 25

<210> 342
<211> 29
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:TPO-MIMETIC

<400> 342
Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala Gly Ile
1 5 10 15

Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala
20 25

<210> 343
<211> 30
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:TPO-MIMETIC

<400> 343
Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala Gly Gly
1 5 10 15

Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala
20 25 30

<210> 344
<211> 31
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:TPO-MIMETIC

<400> 344
Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala Gly Gly
1 5 10 15

Gly Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala
20 25 30

<210> 345
<211> 32
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:TPO-MIMETIC

<400> 345
Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala Gly Gly
1 5 10 15

Gly Gly Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala
20 25 30

<210> 346
<211> 33
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:TPO-MIMETIC

<400> 346
Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala Gly Gly
1 5 10 15

Gly Gly Gly Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg
20 25 30

Ala

<210> 347
<211> 34
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:TPO-MIMETIC

<400> 347
Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala Gly Gly
1 5 10 15

Gly Gly Gly Gly Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala
20 25 30

Arg Ala

<210> 348
<211> 35
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:TPO-MIMETIC

<400> 348
Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala Gly Gly
1 5 10 15

Gly Gly Gly Gly Gly Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala

20 25 30

Ala Arg Ala
35

<210> 349
<211> 36
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:TPO-MIMETIC

<400> 349
Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala Gly Gly
1 5 10 15

Gly Gly Gly Gly Gly Gly Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu
20 25 30

Ala Ala Arg Ala
35

<210> 350
<211> 37
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:TPO-MIMETIC
PEPTIDES

<400> 350
Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala Gly Gly
1 5 10 15

Gly Gly Gly Gly Gly Gly Gly Ile Glu Gly Pro Thr Leu Arg Gln Trp
20 25 30

Leu Ala Ala Arg Ala
35

<210> 351
<211> 38
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:TPO-MIMETIC PEPTIDES

<400> 351
Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala Gly Gly
1 5 10 15

Gly Gly Gly Gly Gly Gly Gly Gly Ile Glu Gly Pro Thr Leu Arg Gln
20 25 30

Trp Leu Ala Ala Arg Ala
35

<210> 352
<211> 42
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:TPO-MIMETIC PEPTIDES

<400> 352
Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala Gly Gly
1 5 10 15

Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Ile Glu Gly Pro
20 25 30

Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala
35 40

<210> 353
<211> 32
<212> PRT
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:TPO-MIMETIC PEPTIDES

<400> 353
Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala Gly Pro
1 5 10 15

Asn Gly Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala
20 25 30

<210> 354
<211> 36
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:TPO-MIMETIC PEPTIDES

<400> 354
Ile Glu Gly Pro Thr Leu Arg Gln Cys Leu Ala Ala Arg Ala Gly Gly
1 5 10 15

Gly Gly Gly Gly Gly Gly Ile Glu Gly Pro Thr Leu Arg Gln Cys Leu
20 25 30

Ala Ala Arg Ala
35

<210> 355
<211> 36
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:TPO-MIMETIC PEPTIDES

<400> 355
Ile Glu Gly Pro Thr Leu Arg Gln Cys Leu Ala Ala Arg Ala Gly Gly
1 5 10 15

Gly Gly Gly Gly Gly Gly Ile Glu Gly Pro Thr Leu Arg Gln Cys Leu
20 25 30

Ala Ala Arg Ala
35

<210> 356
<211> 36
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:TPO-MIMETIC PEPTIDES

<400> 356
Ile Glu Gly Pro Thr Leu Arg Gln Ala Leu Ala Ala Arg Ala Gly Gly
1 5 10 15

Gly Gly Gly Gly Gly Gly Ile Glu Gly Pro Thr Leu Arg Gln Ala Leu
20 25 30

Ala Ala Arg Ala
35

<210> 357
<211> 36
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:TPO-MIMETIC PEPTIDES

<400> 357
Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala Gly Gly
1 5 10 15

Gly Lys Gly Gly Gly Gly Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu
20 25 30

Ala Ala Arg Ala
35

<210> 358
<211> 40
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:TPO-MIMETIC PEPTIDES

<400> 358
Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala Gly Gly
1 5 10 15

Gly Lys Asx Arg Ala Cys Gly Gly Gly Gly Ile Glu Gly Pro Thr Leu
20 25 30

Arg Gln Trp Leu Ala Ala Arg Ala
35 40

<210> 359
<211> 36
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:TPO-MIMETIC PEPTIDES

<400> 359
Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala Gly Gly
1 5 10 15

Gly Cys Gly Gly Gly Gly Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu
20 25 30

Ala Ala Arg Ala
35

<210> 360
<211> 39
<212> PRT

<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:TPO-MIMETIC PEPTIDES

<400> 360
Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala Gly Gly
1 5 10 15

Gly Lys Pro Glu Gly Gly Gly Gly Gly Ile Glu Gly Pro Thr Leu Arg
20 25 30

Gln Trp Leu Ala Ala Arg Ala
35

<210> 361
<211> 39
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:TPO-MIMETIC PEPTIDES

<400> 361
Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala Gly Gly
1 5 10 15

Gly Cys Pro Glu Gly Gly Gly Gly Gly Ile Glu Gly Pro Thr Leu Arg
20 25 30

Gln Trp Leu Ala Ala Arg Ala
35

<210> 362
<211> 36
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:TPO-MIMETIC PEPTIDES